In high-risk outpatients with COVID-19, neither colchicine nor aspirin reduced disease progression or death at 45 d

被引：0
|
作者：
Schectman, Joel M. M. [1 ]
机构：
[1] Univ Virginia Hlth Syst, Charlottesville, VA 22903 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2023年 / 176卷 / 02期
关键词：
D O I：
10.7326/J22-0118
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Eikelboom JW, Jolly SS, Belley-Cote EP, et al.Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised,controlled trial.Lancet Respir Med. 2022;10:1160-8
引用
收藏
页码：JC17 / JC17
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain
    Azanza, Jose Ramon
    Gonzalez Del Castillo, Juan Maria
    Ferrando, Raul
    Molero, Jose Maria
    Soriano, Alex
    Peral, Carmen
    de Lossada, Alfonso
    Bellmunt, Alba
    Gari, Carla
    Mugwagwa, Tendai
    Lopez-Gomez, Vanessa
    JOURNAL OF MEDICAL VIROLOGY, 2025, 97 (03)
  • [32] Early Monoclonal Antibody Administration Can Reduce Both Hospitalizations and Mortality in High-Risk Outpatients With Coronavirus Disease 2019 (COVID-19)
    Jenks, Jeffrey D.
    Aslam, Saima
    Horton, Lucy E.
    Law, Nancy
    Bharti, Ajay
    Logan, Cathy
    Taremi, Mahnaz
    Vaida, Florin
    Ritter, Michele
    CLINICAL INFECTIOUS DISEASES, 2022, 74 (04) : 752 - 753
  • [33] Balancing the Effects of COVID-19 Against Potential Progression and Mortality in High-risk Prostate Cancer
    Moschovas, Marcio Covas
    Sighinolfi, Maria Chiara
    Rocco, Bernardo
    Bhat, Seetharam
    Onol, Fikret
    Rogers, Travis
    Patel, Vipul
    EUROPEAN UROLOGY, 2020, 78 (01) : E14 - E15
  • [34] Reduced seasonal coronavirus incidence in high-risk population groups during the COVID-19 pandemic
    Heiskanen, Aliisa
    Galipeau, Yannick
    Little, Julian
    Langlois, Marc-Andre
    Cooper, Curtis L.
    IMMUNITY INFLAMMATION AND DISEASE, 2024, 12 (07)
  • [35] The impact of the COVID-19 pandemic on negative symptoms in individuals at clinical high-risk for psychosis and outpatients with chronic schizophrenia
    Strauss, Gregory P.
    Macdonald, Kelsey, I
    Ruiz, Ivan
    Raugh, Ian M.
    Bartolomeo, Lisa A.
    James, Sydney H.
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2022, 272 (01) : 17 - 27
  • [36] Clinician Perspectives on Monoclonal Antibody Treatment for High-Risk Outpatients with COVID-19: Implications for Implementation and Equitable Access
    Bethany M. Kwan
    Chelsea Sobczak
    Laurel Beaty
    Matthew K. Wynia
    Matthew DeCamp
    Vanessa Owen
    Adit A. Ginde
    Journal of General Internal Medicine, 2022, 37 : 3426 - 3434
  • [37] Bosentan for high-risk outpatients with COVID-19 infection: a randomized, double blind, placebo-controlled trial
    Shahbazi, Shaahin
    Shariatpanahi, Zahra Vahdat
    Shahbazi, Erfan
    ECLINICALMEDICINE, 2023, 62
  • [38] The impact of the COVID-19 pandemic on negative symptoms in individuals at clinical high-risk for psychosis and outpatients with chronic schizophrenia
    Gregory P. Strauss
    Kelsey I. Macdonald
    Ivan Ruiz
    Ian M. Raugh
    Lisa A. Bartolomeo
    Sydney H. James
    European Archives of Psychiatry and Clinical Neuroscience, 2022, 272 : 17 - 27
  • [39] Clinician Perspectives on Monoclonal Antibody Treatment for High-Risk Outpatients with COVID-19: Implications for Implementation and Equitable Access
    Kwan, Bethany M.
    Sobczak, Chelsea
    Beaty, Laurel
    Wynia, Matthew K.
    DeCamp, Matthew
    Owen, Vanessa
    Ginde, Adit A.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2022, 37 (13) : 3426 - 3434
  • [40] The Impact of the COVID-19 Pandemic on Anal Dysplasia Disease Surveillance in High-Risk Patients
    Sankar, George
    Saberian, Sepehr
    Abdullahi, Dirir
    Clark, Clarence, III
    Chase, Ayana
    Okonkwo, Adatee
    Turner, Jacquelyn S.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2022, 235 (05)
12345